Clinical Trial Update: Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC [Phase 1]

View source ↗

Summary

A Phase 1 dose-finding study evaluating Zanzalintinib in combination with pembrolizumab and cetuximab for head and neck squamous cell carcinoma, currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)
• KEYTRUDA (PEMBROLIZUMAB)
• Zanzalintinib (Zanzalintinib)

Snippet

Sponsor: University of Chicago | Conditions: Head and Neck Neoplasms, Carcinoma, Squamous Cell | Phase 1 | Status: RECRUITING